SCHEMBL1499529

SCHEMBL1499529

CCN(CC)CCCNC(=O)c1ccc(Nc2cccc(C=Cc3ccccn3)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 3/20 0.44
▸ KMT2A Q03164 6/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ HDAC3 O15379 1/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC7 Q8WUI4 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44
▸ HDAC11 Q96DB2 1/20 0.44
▸ HDAC8 Q9BY41 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ HDAC9 Q9UKV0 1/20 0.44
▸ HDAC5 Q9UQL6 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ FLT3 P36888 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499526 1.00 IGF1R (0.44) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL1499341 0.94 KMT2A (0.45) IGF1RKMT2AMEN1NPC1RAB9A
SCHEMBL1499343 0.94 KMT2A (0.45) IGF1RKMT2AMEN1NPC1RAB9A
SCHEMBL1499521 0.92 HDAC6 (0.50) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL1499516 0.92 HDAC6 (0.50) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL1499328 0.91 IGF1R (0.44) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL1499327 0.91 IGF1R (0.44) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL12966945 0.83 BCHE (0.47) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL1499549 0.81 IGF1R (0.45) IGF1RKMT2AMEN1HDAC3HDAC4
SCHEMBL1499548 0.81 IGF1R (0.45) IGF1RKMT2AMEN1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604063-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 — — US claimed
JP-2011509280-A — — 2011-03-24 — — JP claimed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 — — EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 — — WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 — — WO claimed
EP-3536691-B1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2022-10-05 — — EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 — — EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 — — US disclosed
EP-3536691-A1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2019-09-11 — — EP disclosed
US-20190022037-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-01-24 — — US disclosed
US-10130595-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2018-11-20 — — US disclosed
US-20160166519-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CT NATIONALE DE RECH SCIENT (FR) 2016-06-16 — — US disclosed
US-9233931-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2016-01-12 — — US disclosed
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2014-06-05 — — US disclosed
US-8604063-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 — — US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 — — EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 — — WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10130595-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, SF3B1 IGF1R 3594/4885KMT2A 3187/4885MEN1 834/4885
US-20160166519-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, RBM22, SF3B1 IGF1R 3594/4885KMT2A 3187/4885MEN1 834/4885
US-20190022037-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, RBM22, PRPF40A IGF1R 4219/4885KMT2A 4141/4885MEN1 1147/4885
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A IGF1R 4219/4885KMT2A 4141/4885MEN1 1147/4885
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 IGF1R 3832/4885KMT2A 2724/4885MEN1 1067/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 IGF1R 3832/4885KMT2A 2724/4885MEN1 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback